Wall Street analysts expect that Zymeworks Inc (NYSE:ZYME) will report earnings of ($0.62) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Zymeworks’ earnings, with the highest EPS estimate coming in at ($0.60) and the lowest estimate coming in at ($0.63). The firm is expected to announce its next earnings report on Wednesday, February 14th.

On average, analysts expect that Zymeworks will report full-year earnings of ($3.09) per share for the current year, with EPS estimates ranging from ($3.13) to ($3.04). For the next financial year, analysts forecast that the firm will post earnings of ($2.60) per share, with EPS estimates ranging from ($2.71) to ($2.48). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Zymeworks.

Zymeworks (NYSE:ZYME) last posted its earnings results on Wednesday, November 8th. The company reported ($0.65) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.09. Zymeworks had a negative return on equity of 117.85% and a negative net margin of 1,387.89%.

Several analysts have recently weighed in on the company. Cormark reissued a “buy” rating on shares of Zymeworks in a report on Saturday, September 30th. Zacks Investment Research raised Zymeworks from a “sell” rating to a “hold” rating in a report on Thursday, October 12th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $14.35.

Shares of Zymeworks (ZYME) opened at $9.49 on Tuesday. Zymeworks has a fifty-two week low of $6.25 and a fifty-two week high of $14.25.

An institutional investor recently bought a new position in Zymeworks stock. OxFORD Asset Management LLP bought a new stake in Zymeworks Inc (NYSE:ZYME) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 18,467 shares of the company’s stock, valued at approximately $154,000. OxFORD Asset Management LLP owned about 0.07% of Zymeworks as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 7.20% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Brokerages Anticipate Zymeworks Inc (ZYME) Will Announce Earnings of -$0.62 Per Share” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://theolympiareport.com/2018/01/16/brokerages-anticipate-zymeworks-inc-zyme-will-announce-earnings-of-0-62-per-share.html.

Zymeworks Company Profile

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins.

Get a free copy of the Zacks research report on Zymeworks (ZYME)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.